Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

about

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.

Item

http://www.wikidata.org/entity/Q40015002

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Allogeneic hematopoietic cell ...... nsformed follicular lymphomas.

@en

type

Item

label

Allogeneic hematopoietic cell ...... nsformed follicular lymphomas.

@en

prefLabel

Allogeneic hematopoietic cell ...... nsformed follicular lymphomas.

@en

P1476

Allogeneic hematopoietic cell ...... nsformed follicular lymphomas.

@en

P2093

A Müller

http://www.w3.org/2001/XMLSchema#string

C Müller

http://www.w3.org/2001/XMLSchema#string

D Bunjes

http://www.w3.org/2001/XMLSchema#string

D Niederwieser

http://www.w3.org/2001/XMLSchema#string

D W Beelen

http://www.w3.org/2001/XMLSchema#string

E Holler

http://www.w3.org/2001/XMLSchema#string

F Heinzelmann

http://www.w3.org/2001/XMLSchema#string

G Kobbe

http://www.w3.org/2001/XMLSchema#string

H Baurmann

http://www.w3.org/2001/XMLSchema#string

H Ottinger

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

P2888

bmt.2015.348

P304

654-662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2015.348

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003537707

http://www.w3.org/2001/XMLSchema#string

P698

26855152

http://www.w3.org/2001/XMLSchema#string